Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PENTO protocol in MRONJ
2024-518688-36-00Phase 2Authorised
- Sponsor
- CHU de Limoges
- Start
- Oct 2024
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pentoxifylline, tocopherol, amoxicillin + clavulanate and clindamycin in medication-related osteonecrosis of the jaw (MRONJ), sponsored by CHU de Limoges. Primary endpoint: Healing rate at 12 months. Planned start Oct 2024; status: authorised.
02
Drugs
pentoxifyllinetocopherolamoxicillin + clavulanateclindamycin
03
Conditions
medication-related osteonecrosis of the jaw (MRONJ)
Beyond the preview
Go deeper on 2024-518688-36-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-518688-36-00.